10-K: Aditxt, Inc. Reports 2023 Annual Results, Faces Going Concern Doubts

Aditxt, Inc.'s 2023 annual report reveals a significant net loss and raises substantial doubt about the company's ability to continue as a going concern.

Summary

• Aditxt, Inc. reported a net loss of $32.39 million for the year ended December 31, 2023, compared to a net loss of $27.65 million in 2022.
• The company's accumulated deficit as of December 31, 2023, was $127.64 million.
• Aditxt generated revenue of $645,176 in 2023, a decrease from $933,715 in 2022.
• The company's operating loss for 2023 was $26.06 million, primarily due to general and administrative expenses of $18.61 million and research and development expenses of $7.07 million.
• The report indicates that the company's current cash reserves may not be sufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
• The company is over 90 days past due on a significant number of vendor obligations.
• Aditxt is actively seeking additional capital through various means, including equity and debt financing, and strategic collaborations.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant losses, declining revenue, and doubts about the company's ability to continue as a going concern. While there are some positive aspects related to the company's technology and subsidiaries, the overall sentiment is negative due to the financial instability and operational challenges.

Positives

• Aditxt has formed three subsidiaries: Adimune, Pearsanta, and Adivir, to focus on specific areas of innovation.
• Adimune is advancing clinical studies for its immune modulation therapy, ADI-100, with a focus on Stiff Person Syndrome.
• Pearsanta is developing a platform for personalized medicine, including the AditxtScore technology for immune profiling.
• Adivir is dedicated to the development of antiviral and anti-infective products.
• The company has secured licenses for key technologies from Loma Linda University and Stanford University.

Negatives

• The company has generated no significant revenue from commercial sales to date.
• Aditxt has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future.
• The company is currently over 90 days past due on a significant number of vendor obligations.
• The company is in arrears on multiple lease agreements.
• The company's financial situation creates doubt about its ability to continue as a going concern.
• The company may need to raise additional funding, which may not be available on acceptable terms, or at all.
• The company faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than they do.

Risks

• The company's future profitability is uncertain, and it may not be able to achieve profitability.
• Failure to obtain necessary capital could force the company to delay, scale back, or eliminate research and development activities.
• The regulatory approval process is expensive, time-consuming, and uncertain, and may prevent the company from obtaining approvals for its product candidates.
• The company may encounter substantial delays in completing clinical studies, which could increase costs and jeopardize its ability to generate revenue.
• The company's technologies and products under development may fail if they are not successfully commercialized.
• The company relies on third parties for manufacturing and distribution, which could lead to delays or other issues.
• The company may be subject to claims by third parties asserting that its employees or it have misappropriated their intellectual property.
• The company is under a panel monitor from Nasdaq, and failure to comply with listing requirements could result in delisting.
• Future sales or issuances of substantial amounts of the company's common stock could result in significant dilution.

Future Outlook

The company expects to incur additional net expenses over the next several years as it continues to maintain and expand its existing operations. The amount of future losses and when, if ever, the company will achieve profitability are uncertain. The company will need significant additional capital to continue to fund its operations and the clinical trials for its product candidates.

Management Comments

• We believe the world needsand deservesa new approach to innovating that harnesses the power of large groups of stakeholders who work together to ensure that the most promising innovations make it into the hands of people who need them most.
• We seek to enable promising innovation to become purposeful products that have the power to change lives.
• We believe that the era of precision and personalized medicine is here and that people around the globe would benefit from health diagnostics and treatments that more accurately pinpoint the problems and more precisely treat the condition.

Industry Context

The document highlights the competitive landscape in the pharmaceutical and biotechnology industries, noting that Aditxt competes with a variety of multinational pharmaceutical companies and specialized biotechnology companies, as well as products and processes being developed at universities and other research institutions. The company also notes that mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of competitors.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• However, it does mention that many of Aditxt's competitors have significantly greater financial, technical, and human resources, which may give them a competitive advantage.
• The document also notes that the development and commercialization of drugs is highly competitive, and that many products are currently available, under development, and may become commercially available in the future, for the treatment of indications for which Aditxt may try to develop product candidates.
• The document does not provide specific comparisons to other companies in the same sector, but it does note that smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

Legal Proceedings

• The Company, Amro Albanna, our Chief Executive Officer, and Dr. Shahrokh Shabahang, our Chief Innovation Officer, have been named as cross-defendants in a counterclaim filed by Christopher Sechrist in an action entitled Shahrokh Shabahang v. Christopher Sechrist, San Bernardino County Superior Court Case No. CIVDS1831323.
• Our Chief Executive Officer, Amro Albanna, is a party to litigation matters unrelated to the Company or any of its properties. Such litigations relate to Innovation Economy Corporation (IEC), a company in which Mr. Albanna served as the CEO and a Director from 2010 until 2017, and its wholly-owned subsidiaries (Innovation Economy Corporation d/b/a ieCrowd).

Related Party Transactions

• Amro Albanna, the Chief Executive Officer of the Company, and Shahrokh Shabahang, the Chief Innovation Officer of the Company, loaned $117,000 and $115,000, respectively, to the Company on February 29, 2024.
• Amro Albanna, the Chief Executive Officer of the Company loaned $205,000 to the Company on February 15, 2024.
• Amro Albanna, the Chief Executive Officer of the Company loaned $30,000 to the Company on February 7, 2024.
• Amro Albanna, the Chief Executive Officer of the Company loaned $165,000 to the Company on December 20, 2023.
• Amro Albanna, the Chief Executive Officer of the Company loaned $200,000 to the Company on December 6, 2023.
• Amro Albanna, the Chief Executive Officer of the Company loaned $10,000 to the Company on November 30, 2023.
• Amro Albanna, the Chief Executive Officer of the Company and Shahrokh Shabahang, the Chief Innovation Officer of the Company, loaned $200,000 and $100,000, respectively, to the Company on June 12, 2023.
• Amro Albanna, the Chief Executive Officer of the Company, and Shahrokh Shabahang, the Chief Innovation Officer of the Company, loaned $87,523 and $100,000, respectively, to the Company on April 21, 2023.
• Amro Albanna, the Chief Executive Officer of the Company, loaned $200,000 to the Company on May 25, 2023.
• Amro Albanna, the Chief Executive Officer of the Company, and Shahrokh Shabahang, the Chief Innovation Officer of the Company, loaned $200,000 and $100,000, respectively, to the Company on June 12, 2023.
• The Company issued one share of Series C Preferred Stock to Amro Albanna, its Chief Executive Officer, for $1,000 in cash on July 11, 2023.
• The Company issued one share of Series B Preferred Stock to Amro Albanna, its Chief Executive Officer, for $20,000 in cash on July 19, 2022.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential delisting from Nasdaq.
• Employees may be concerned about job security due to the company's going concern doubts.
• Customers may be hesitant to adopt the company's products due to the uncertainty surrounding its future.
• Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will continue to seek additional capital to fund its operations and clinical trials.
• The company will continue to develop and commercialize its technologies and product candidates.
• The company will continue to monitor its compliance with Nasdaq listing requirements.

Key Dates

Keywords

Aditxt, Immunotherapy, Personalized Medicine, Diagnostics, Biotechnology, Clinical Trials, Regulatory Approval, Financial Results, Going Concern, Capital Raise